Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Hold” from Brokerages

Galapagos NV (NASDAQ:GLPG) has been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $34.50.

A number of brokerages have recently weighed in on GLPG. Morgan Stanley began coverage on shares of Galapagos in a report on Thursday, March 7th. They set an “equal weight” rating and a $38.00 price target for the company. Bank of America reaffirmed an “underperform” rating and set a $31.00 price target (down previously from $41.00) on shares of Galapagos in a report on Thursday, March 28th. Finally, StockNews.com downgraded shares of Galapagos from a “buy” rating to a “hold” rating in a report on Monday, March 18th.

Hedge Funds Weigh In On Galapagos

Several large investors have recently bought and sold shares of GLPG. Quadrant Capital Group LLC grew its holdings in shares of Galapagos by 18.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 261 shares during the last quarter. Wellington Management Group LLP boosted its position in Galapagos by 1.8% during the 1st quarter. Wellington Management Group LLP now owns 16,575 shares of the biotechnology company’s stock worth $1,028,000 after buying an additional 293 shares during the period. BNP Paribas Financial Markets boosted its position in Galapagos by 96.4% during the 4th quarter. BNP Paribas Financial Markets now owns 603 shares of the biotechnology company’s stock worth $25,000 after buying an additional 296 shares during the period. Monaco Asset Management SAM boosted its position in Galapagos by 3.8% during the 3rd quarter. Monaco Asset Management SAM now owns 8,458 shares of the biotechnology company’s stock worth $292,000 after buying an additional 313 shares during the period. Finally, Citigroup Inc. boosted its position in Galapagos by 29.0% during the 4th quarter. Citigroup Inc. now owns 1,733 shares of the biotechnology company’s stock worth $77,000 after buying an additional 390 shares during the period. 32.46% of the stock is currently owned by institutional investors.

Galapagos Trading Down 1.5 %

Shares of Galapagos stock opened at $29.80 on Tuesday. The company has a 50 day moving average of $34.91 and a 200-day moving average of $36.59. Galapagos has a 1-year low of $29.79 and a 1-year high of $45.21. The company has a market cap of $1.96 billion, a PE ratio of -13.01 and a beta of 0.25.

About Galapagos

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.